| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Fortress Biotech, Inc.$3.16
+0.08 (+2.6%)
D 35Pipeline Score Overvalued Pharma · Commercial
Market Cap
91.02 M
EPS
3.87
P/E Ratio
0.86 $
Value Trade
738.60 K
SEC Financials
Q1 2026Dilution Risk
Revenue
16.04 M
R&D Expenses
540.00 K
Operating CF
203.85 M
Total Assets
356.87 M
Total Liabilities
154.50 M
Equity
162.21 M
D/E Ratio
12,345
16.6 %
Week
21.78 %
1 Month
-20.35 %
3 Month
9.16 %
6 Month
-95.25 %
5 Year
-97.72 %
All Time
Cash Data
Cash Position
255.84 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
791.59 K
52 Week Range
1.70 - 4.53
% held by Insiders
31.02 %
% held by Institutions
16.31 %
Enterprise Value
-71.02 M
Total Shares
31.04 M
Short %
20.79 %
Float Shares
24.49 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $49M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.5x
rNPV / MCap Top 47%
Micro Cap (rank 481 of 905)
Percentile RankFortress Biotech, Inc. faces pipeline headwinds (35/100), with $395M risk-adjusted pipeline value, led by Copper Histidine in Menkes Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Copper Histidine Small molecule | Menkes Disease | Phase 3 | NCT00811785 | 55% | $260M | COMPLETED | 93 | - | - | Aug 28, 2020 | - | Nov 19, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
FBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FBIO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
FBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FBIOFortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Fortress Biotech, Inc. will participate in A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. CEO Lindsay A. Rosenwald will engage in a fireside chat during the event. Fortress focuses on acquiring and advancing biopharmaceutical assets to enhance shareholder value through various revenue streams.
Read more →FBIOFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights ZYCUBO approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale
Fortress Biotech announced its financial results for Q1 2026, reporting a net income of $108.4 million and the FDA approval of ZYCUBO for the treatment of Menkes disease. The company also highlighted the successful sale of its Rare Pediatric Disease Priority Review Voucher for $205 million. With ongoing development initiatives and expectations for increased royalty revenue, Fortress is strategically positioned to enhance shareholder value. CEO Lindsay A. Rosenwald emphasized the company’s focus on strengthening its balance sheet and expanding its pipeline through acquisitions.
Read more →FBIOFortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Fortress Biotech, Inc. will participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026. CEO Lindsay A. Rosenwald will engage in a fireside chat at the event. Fortress Biotech focuses on acquiring and advancing biopharmaceutical assets to enhance shareholder value through various revenue streams.
Read more →FBIOFortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech reported significant financial results for 2025, highlighting the FDA approval of ZYCUBO® for Menkes disease and the $205 million sale of a Rare Pediatric Disease Priority Review Voucher. The acquisition of Checkpoint Therapeutics by Sun Pharma further strengthens Fortress's revenue model. Additionally, the progression of dotinurad into Phase 3 indicates ongoing advancements in their clinical portfolio.
Read more →FBIOFortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's subsidiary, Cyprium Therapeutics, has successfully sold its Rare Pediatric Disease Priority Review Voucher for $205 million. This transaction is expected to provide significant financial benefits to Fortress, allowing for further investments in its diverse portfolio. The sale follows recent FDA approvals for multiple products, highlighting the company's growth and strategic direction.
Read more →FBIOUPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's subsidiary, Cyprium Therapeutics, has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205 million. This transaction follows the FDA approval of ZYCUBO for Menkes disease. Cyprium will also receive royalties and milestone payments from Sentynl Therapeutics, which has taken over ZYCUBO's commercialization.
Read more →FBIOFortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's subsidiary, Cyprium Therapeutics, has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205 million. This PRV was awarded following the FDA approval of ZYCUBO for Menkes disease. Cyprium is also set to receive tiered royalties and milestone payments from Sentynl Therapeutics, which has taken over ZYCUBO's commercialization. The transaction is subject to customary closing conditions.
Read more →FBIOAvenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Avenue Therapeutics has secured an exclusive worldwide license for ATX-04, a selective β2-adrenergic agonist, from Duke University. This drug, currently in clinical development for Pompe disease, has shown significant improvements in muscle function and response to enzyme replacement therapy. The agreement allows Avenue to advance ATX-04 through late-stage clinical development, with potential applications in related neuromuscular conditions.
Read more →FBIOstreams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of products und
Fortress Biotech's subsidiary, Cyprium Therapeutics, announced a $205 million agreement to sell a Rare Pediatric Disease Priority Review Voucher after receiving FDA approval for its drug, ZYCUBO, for Menkes disease. The sale demonstrates Cyprium's ability to execute value-generating corporate transactions and signals the company's ongoing progress in developing therapies for rare diseases. Insights from Fortress CEO Lindsay Rosenwald highlight the company’s strong position following three FDA approvals in the past 15 months. The transaction is subject to customary closing conditions.
Read more →FBIOFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Fortress Biotech and Cyprium Therapeutics have announced the FDA approval of ZYCUBO (copper histidinate) as the first treatment for Menkes disease in pediatric patients. The approval includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium. ZYCUBO has demonstrated significant improvements in overall survival rates for treated patients compared to untreated controls. However, the treatment carries risks of copper accumulation and various adverse reactions.
Read more →FBIOFortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
Fortress Biotech and Cyprium Therapeutics announced the FDA's acceptance of the NDA resubmission for CUTX-101, aimed at treating Menkes disease in children. The resubmission is classified as Class 1, with a PDUFA action date set for January 14, 2026. The NDA follows a complete response letter from the FDA that raised concerns about manufacturing compliance but did not question the drug's efficacy or safety.
Read more →FBIOpredicts," "should," or "will" or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management's curr
Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the FDA's acceptance of the NDA resubmission for CUTX-101, intended for treating Menkes disease. The new PDUFA target action date is set for January 14, 2026. Sentynl Therapeutics, having taken over the development responsibilities, resubmitted the NDA after addressing previous compliance concerns. The therapy shows promise, demonstrating significant improvements in survival for pediatric patients, while the collaboration could yield substantial financial benefits for Cyprium.
Read more →FBIOFortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress su
Fortress Biotech reported promising financial results for Q3 2025, with a 20.5% increase in net revenue to $17.6 million compared to the previous year. Significant corporate highlights include the acquisition of Checkpoint Therapeutics by Sun Pharma, bringing Fortress ~$28 million and potential future royalties. The company is also advancing dotinurad in two Phase 3 trials and is poised to resubmit a New Drug Application for CUTX-101. Despite these positives, Fortress faces uncertainties related to future revenue streams and product development phases.
Read more →FBIOFortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
Fortress Biotech's subsidiary, Urica Therapeutics, has initiated Phase 3 trials for dotinurad, a new treatment for gout. The RUBY and TOPAZ studies will evaluate the drug's safety and efficacy in patients with hyperuricemia and tophaceous gout, respectively. This marks a critical advancement in addressing unmet needs in gout treatment.
Read more →FBIOFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Urica Therapeutics, a subsidiary of Fortress Biotech, announced that Crystalys Therapeutics has closed a $205 million Series A financing to advance Phase 3 clinical trials for dotinurad, a next-generation URAT1 inhibitor for gout. The financing was co-led by notable investors and aims to expedite the drug's development in the U.S. and Europe. Fortress Biotech will benefit from an equity stake and future royalties from dotinurad's sales.
Read more →FBIOFortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Fortress Biotech and Cyprium Therapeutics announced that the FDA issued a Complete Response Letter regarding the NDA for CUTX-101, intended for treating Menkes disease. The letter cited cGMP deficiencies at the manufacturing facility but did not raise concerns about the drug's efficacy or safety. Cyprium's partner, Sentynl Therapeutics, plans to address the FDA's concerns and resubmit the NDA.
Read more →FBIOFortress Biotech Investigated by the Portnoy Law Firm
Fortress Biotech Inc. is currently under investigation by the Portnoy Law Firm for potential securities fraud, following an announcement concerning a Complete Response Letter from the FDA. The letter noted that deficiencies at the manufacturing facility for CUTX-101 were observed, which raised concerns among investors. This development has led to a significant drop in the company's stock price. Investors are being urged to explore potential claims for recovery of losses linked to this corporate wrongdoing.
Read more →FBIOstatements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could c
Fortress Biotech and its subsidiary, Cyprium Therapeutics, received a Complete Response Letter from the FDA regarding the New Drug Application for CUTX-101, an investigational treatment for Menkes disease. The CRL cited cGMP deficiencies at the manufacturing facility, while noting no concerns about the drug's efficacy or safety data. Following the CRL, Cyprium plans to work with its partner, Sentynl Therapeutics, to address the FDA's issues and pursue a resubmission of the NDA. Additionally, the partnership includes potential financial incentives such as a Rare Pediatric Disease Priority Review Voucher and milestone payments.
Read more →FBIOFortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Fortress Biotech, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, with CEO Lindsay A. Rosenwald providing a corporate overview. The presentation will be available for on-demand viewing starting September 5, 2025. The company will also participate in virtual one-on-one meetings during the conference from September 8-11, 2025.
Read more →FBIOFortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech reported strong financial results for Q2 2025, highlighted by the acquisition of Checkpoint Therapeutics by Sun Pharma, which provided $28 million upfront and potential future royalties. The FDA has accepted the New Drug Application for CUTX-101, aimed at treating Menkes disease, with a goal date set for September 30, 2025. Additionally, the company launched Emrosi™ for rosacea treatment, marking significant progress in its portfolio.
Read more →FBIOFortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress Biotech announced the successful acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharmaceutical Industries. The deal, finalized on May 30, 2025, follows shareholder approval and aims to improve patient access to the FDA-approved drug UNLOXCYT. Fortress is set to receive $28 million and a 2.5% royalty on net sales, marking a significant milestone in their growth strategy.
Read more →FBIOFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoi
Fortress Biotech, Inc. reported its first quarter financial results for 2025, highlighting the launch of Emrosi, a treatment for rosacea. The company also noted the acceptance of its New Drug Application for CUTX-101 aimed at Menkes disease, with a PDUFA date of September 30, 2025. Additionally, a merger agreement was reached for Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma, which is anticipated to enhance patient access and provide monetization opportunities for Fortress. Overall, the company presents continued optimism regarding its growth trajectory and product pipeline.
Read more →FBIOFortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
Fortress Biotech, Inc. will participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025. Dr. Lindsay A. Rosenwald, the company's Chairman and CEO, will represent Fortress at the event. The company focuses on enhancing shareholder value through various revenue streams and has a diverse portfolio in multiple therapeutic areas.
Read more →FBIOFortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights Emrosi approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution
Fortress Biotech reported strong financial results for 2024, highlighted by the FDA's approval of Emrosi for inflammatory lesions of rosacea and UNLOXCYT for skin cancer. The company is moving forward with commercializing these products and anticipates significant revenue growth. Additionally, Checkpoint Therapeutics, a subsidiary of Fortress, will be acquired by Sun Pharma, which promises to improve patient access to their approved products. Looking ahead, Fortress is preparing for regulatory advancements, including the upcoming PDUFA goal date for CUTX-101.
Read more →FBIOPartex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
Partex NV and Fortress Biotech, Inc. have announced a strategic collaboration to utilize Partex's AI-driven platform for identifying and evaluating biopharmaceutical compounds. This partnership aims to enhance Fortress's ability to acquire and license promising assets efficiently. The collaboration is expected to accelerate the development of innovative therapeutics across various therapeutic areas.
Read more →FBIOFortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
Fortress Biotech has initiated a Phase 2 clinical trial for its Triplex vaccination aimed at reducing cytomegalovirus (CMV) events in patients receiving hematopoietic stem cell transplants from vaccinated donors. This randomized, controlled trial is the first of its kind, funded by the National Cancer Institute, and seeks to evaluate the vaccine's effectiveness and safety. Prior pilot studies have indicated that Triplex may provide protective CMV-specific T cell immunity, potentially improving recovery outcomes for transplant recipients. If successful, this novel approach might also reduce the need for antiviral medications that can complicate recovery.
Read more →FBIOFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Fortress Biotech and its subsidiary, Cyprium Therapeutics, announced the acceptance of the NDA for CUTX-101 by the FDA for the treatment of Menkes disease, a rare pediatric condition. The NDA has been granted a Priority Review designation, with a target date for action set for June 30, 2025. Positive clinical data supports the submission, showing significant improvements in survival rates for patients receiving early treatment with CUTX-101. Cyprium is also eligible for royalties and potential milestones upon NDA approval from Sentynl Therapeutics, which will commercialize the product.
Read more →FBIOFortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal dat
Fortress Biotech announced its third quarter 2024 financial results, highlighting significant achievements, including FDA approval for Emrosi, a treatment for rosacea. Additionally, the company anticipates further growth with a PDUFA goal date set for cosibelimab's approval in December. Fortress is focused on expanding its portfolio through innovative therapies and has several ongoing development programs. The CEO expressed optimism about building shareholder value and addressing unmet medical needs in various therapeutic areas.
Read more →FBIOFortress Biotech to Participate in October 2024 Investor Conferences
Fortress Biotech, Inc. has announced its participation in two significant investor conferences in October 2024. Dr. Lindsay A. Rosenwald, the company's Chairman and CEO, will present at the Lytham Partners Fall 2024 Investor Conference on October 1 and at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9. Fortress Biotech is focused on enhancing shareholder value through a diverse portfolio that includes marketed pharmaceuticals and extensive development programs across various therapeutic areas.
Read more →FBIOBiotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
Fortress Biotech, Inc. announced the pricing of an $8 million registered direct offering, selling nearly 4 million shares at $1.65 each to institutional investors. Concurrently, the company is issuing warrants for additional shares as part of the deal. The funds raised will support various operational expenses, including research and development costs. A notable insider, the Chairman and CEO, also participated in a separate private placement, indicating confidence in the company’s future.
Read more →FBIOFortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
Fortress Biotech has announced a registered direct offering to raise $8 million through the sale of approximately 3.9 million shares at $1.65 each. Concurrently, a private placement is being conducted involving insider purchases of common stock and warrants. The proceeds from these offerings will support the company's operations and development initiatives. These actions demonstrate Fortress Biotech’s focus on maximizing shareholder value through strategic financing.
Read more →FBIOFortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fortress Biotech, Inc. (Nasdaq: FBIO) has announced a corporate overview presentation by its CEO, Lindsay A. Rosenwald, at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing starting on September 9, 2024. Fortress, which has seven marketed pharmaceutical products and numerous programs in development, is focused on enhancing shareholder value through strategic acquisitions and partnerships in sectors such as oncology and gene therapy.
Read more →FBIOFortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PDUFA goal date of
Fortress Biotech has reported its second quarter 2024 financial results and noted several corporate highlights. The company anticipates an exciting second half of the year with two pivotal drug applications pending with the FDA, including DFD-29 for rosacea and cosibelimab for skin cancer treatment. These applications, with goal dates in late 2024, hold the potential for up to three regulatory approvals over the next year. Fortress also highlighted a 15% increase in product revenue, signaling strong performance in its dermatology segment.
Read more →FBIOFortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 Extends maturity of long-term debt as Fortress' late-stage pipeline continues to advance and may generate u
Fortress Biotech announced it has entered into a loan agreement with Oaktree Capital Management, securing an initial $35 million to enhance its financial flexibility while advancing its late-stage pipeline. The new loan allows Fortress to repay a prior $50 million debt, extending the maturity to July 2027. The company projects up to three regulatory approvals within the next year and a potential fourth filing in 2025. This strategic financial move is aimed at supporting Fortress's initiatives in acquiring and developing new assets.
Read more →FBIOFortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Miami, FL
Fortress Biotech, Inc. has announced a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, effective July 1, 2024. The Board of Directors believes this decision is necessary to maintain financial flexibility as the company anticipates potential significant regulatory milestones. The suspension will defer about $0.7 million in cash dividends each month, although dividends will continue to accrue. This strategic pause aims to position Fortress favorably ahead of multiple potential near-term approvals and commercial opportunities.
Read more →FBIOFortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
Fortress Biotech, Inc., an innovative biopharmaceutical company, announced the participation of its CEO, Lindsay A. Rosenwald, in the Alliance Global Partners Virtual Healthcare Company Showcase on May 21, 2024. This event highlights the company's focus on acquiring and advancing biopharmaceutical assets. Fortress has a comprehensive portfolio consisting of seven marketed prescription products and over 20 programs in development across various therapeutic areas including oncology and rare diseases. A replay of the discussion will be available on the company's website after the event.
Read more →FBIOFortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Fortress late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the ne
Fortress Biotech reported its financial results for the first quarter of 2024, highlighting anticipated regulatory approvals for multiple products in the pipeline, including DFD-29 for rosacea. The FDA acceptance of the NDA for DFD-29 is a significant milestone. However, the company faced a setback with the complete response letter received for the cosibelimab BLA due to manufacturing concerns. Fortress is optimistic about further growth in product revenues, bolstered by a strong clinical program and sizeable investments in development-stage products across diverse therapeutic areas.
Read more →FBIOFortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
Fortress Biotech has announced the dosing of the first patient in a Phase 2 clinical trial for Triplex, a CMV vaccine aimed at liver transplant patients. The study, funded by a $9 million NIH/NIAID grant, will evaluate Triplex's safety and effectiveness in improving patient outcomes. Conducted across 20 transplant centers, the trial could address the significant unmet need regarding CMV complications in organ transplantation. The vaccine is designed to induce an immune response against CMV, which poses serious risks for patients with weakened immune systems.
Read more →FBIOFortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in
Fortress Biotech, Inc. reported record consolidated net revenue of $84.5 million for the full year of 2023 and highlighted significant regulatory achievements, including the acceptance of an NDA for DFD-29 by the FDA with a PDUFA goal date of November 4, 2024. The company is optimistic about the possibility of receiving up to four regulatory decisions on NDAs and BLAs within the next 18 months while advancing its pipeline of 25 development-stage programs. Despite positive momentum, the company also faces challenges related to its financial obligations and the need for additional funding.
Read more →FBIOFortress Biotech to Participate in 36th Annual ROTH Conference
Fortress Biotech, Inc. (NASDAQ: FBIO) will participate in the 36th Annual ROTH Conference on March 18, 2024. CEO Lindsay A. Rosenwald is scheduled for a fireside chat, which will be webcasted and accessible for 30 days on the company's website. Fortress Biotech is known for its diverse pipeline, including over 25 development programs in therapeutics spanning oncology, rare diseases, and gene therapy.
Read more →FBIOFortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Cyprium Therapeutics, a subsidiary of Fortress Biotech, has announced a grant of approximately $4.1 million from the NINDS to support the development of AAV-ATP7A gene therapy for Menkes disease. This funding will facilitate preclinical studies and the manufacturing process for a forthcoming Investigational New Drug application. The gene therapy aims to be used alongside CUTX-101, potentially creating the first FDA-approved treatment for the disorder. Encouraging preclinical results have indicated a promising combination effect in mouse models.
Read more →FBIOFortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Fortress Biotech, Inc. announced the successful closing of an $11 million registered direct offering, issuing over 3.3 million shares of common stock along with warrants. The offering was priced at $3.33 per share, under Nasdaq rules, with warrants exercisable at $3.21. The transaction is expected to bolster Fortress's financial position as it continues to develop its diverse pipeline of therapeutic products. Roth Capital Partners acted as the exclusive placement agent for the offering.
Read more →FBIOFortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Miami, FL
Fortress Biotech, Inc. has declared a definitive agreement for a registered direct offering, pricing 3,303,305 shares of common stock along with warrants at $3.33 per share. The offering is expected to generate approximately $11 million in gross proceeds, aimed at supporting operational expenses, including R&D and working capital. The transaction, handled by Roth Capital Partners, is anticipated to close on January 3, 2024, subject to customary closing conditions. This financing strategy indicates Fortress's commitment to expanding its therapeutic product pipeline and operational capabilities.
Read more →FBIOFortress Biotech Announces Closing of $10.0 Million Public Offering
Fortress Biotech, Inc. has announced the successful closing of its public offering, which raised approximately $10 million by issuing 5,885,000 units at $1.70 each. The offering included direct purchases from certain directors and officers, amounting to around $2.9 million. The net proceeds from this offering will be utilized for operational purposes, including research and development, clinical trials, and working capital. Roth Capital Partners acted as the exclusive placement agent for this transaction.
Read more →FBIOFortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net rev
Fortress Biotech reported a substantial increase in consolidated net revenue for the third quarter of 2023, reaching $34.8 million, attributed to an exclusive licensing agreement. The company is set to submit multiple New Drug Applications (NDAs) and Biologics License Applications (BLAs) to the FDA through the end of 2024, with a NDA for DFD-29 targeting rosacea expected soon. Fortress is also progressing on its investigational drug cosibelimab, which aims to treat advanced skin cancer. Despite this success, concerns linger regarding the company's significant reduction in cash reserves and dependency on collaborations for revenue growth.
Read more →FBIOFortress Biotech Announces Pricing of $10.0 Million Public Offering
Fortress Biotech has priced a public offering of 5,885,000 units, generating expected gross proceeds of $10 million. Each unit is priced at $1.70 and includes one share of common stock and one warrant to purchase an additional share at the same price. The offering is set to close on or around November 14, 2023, subject to customary conditions. Proceeds from this initiative will primarily support company operations, research, and development activities.
Read more →FBIOFortress Biotech Announces Launch of Proposed Public Offering Miami, FL
Fortress Biotech, Inc. has announced the commencement of a proposed public offering to sell units comprising common stock and warrants. The final terms will depend on market conditions, and there is no guarantee on the completion of the offering. Proceeds from this offering are expected to support various operational needs, including research and development and working capital. The company has a strong pipeline with multiple products in development, highlighting its commitment to therapeutic innovation.
Read more →FBIOFortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Fortress Biotech's subsidiary, Helocyte, has entered an exclusive option agreement with City of Hope for the use of a novel bispecific CMV/HIV CAR T cell therapy. This agreement comes alongside a recent $11.3 million grant from CIRM to support a Phase 1 clinical trial at City of Hope. The trial aims to evaluate the safety and efficacy of the therapy in adults living with HIV-1. Preclinical studies have suggested that the therapy may effectively eradicate HIV from latent reservoirs, offering potential for significant advancements in treatment options.
Read more →FBIOFortress Biotech Announces Reverse Stock Split
Fortress Biotech, Inc. has announced a 1-for-15 reverse stock split of its common stock, effective October 10, 2023, to comply with Nasdaq's minimum bid price requirement. The Board of Directors approved this measure at a special meeting, reducing the number of outstanding shares from approximately 134.1 million to about 8.9 million. Fortress intends to maximize shareholder value through this restructuring, while continuing to pursue its development programs across various therapeutic areas. Stockholders will be informed regarding the exchange process for their shares.
Read more →FBIOFortress Biotech Announces Reverse Stock Split Miami, FL
Fortress Biotech, Inc. has announced a 1-for-15 reverse stock split of its common stock, effective October 10, 2023. This move is a strategic effort to comply with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse stock split was approved by both the company's Board of Directors and stockholders, aiming to reduce the number of outstanding shares significantly. Following the split, the stock will continue to trade on the Nasdaq under the symbol FBIO, although the reduction in shares is a reflection of challenges faced by the company in maintaining its market valuation.
Read more →FBIOFortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
Fortress Biotech, Inc. will present a corporate overview at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City. The presentation, led by CEO Lindsay A. Rosenwald, is scheduled for October 12, 2023. Fortress Biotech focuses on the acquisition and commercialization of promising therapeutic products, boasting a diverse pipeline with eight marketed products and numerous ongoing projects in various therapeutic areas, including oncology and rare diseases.
Read more →FBIOFortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
Fortress Biotech, Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. CEO Lindsay A. Rosenwald will lead the presentation, which will also include one-on-one meetings at the event. Fortress Biotech is recognized for its innovative approach in developing and commercializing therapeutic products, with a significant pipeline of market-ready and developmental treatments. Their collaboration with leading institutions enhances their market position and product opportunities.
Read more →FBIOFortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of
Fortress Biotech, Inc. reported financial results for the second quarter of 2023, revealing a significant 40% increase in net revenue to $17.4 million. The company highlighted positive topline results from two Phase 3 trials for its DFD-29 treatment and plans to submit two New Drug Applications in the second half of the year. The PDUFA goal date for cosibelimab is set for January 3, 2024, indicating progress in their product pipeline. However, the company reported a substantial net loss which raises concerns about its financial sustainability despite the positive revenue growth.
Read more →FBIOFortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
Fortress Biotech, Inc. will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 8, 2023. Chairman, President, and CEO Lindsay A. Rosenwald will lead the presentation, which will also include virtual one-on-one meetings. The company focuses on acquiring, developing, and commercializing therapeutic products with a diverse pipeline spanning oncology, rare diseases, and gene therapy. Fortress has established multiple partnerships with prominent academic and biopharmaceutical organizations to enhance their development efforts.
Read more →FBIOFortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goa
Fortress Biotech has reported its financial results for the first quarter of 2023 alongside significant corporate updates. The company is advancing several late-stage clinical assets, with two New Drug Application (NDA) submissions expected by the end of the year. Notably, the FDA has set a PDUFA goal date of January 3, 2024, for cosibelimab, aimed at treating metastatic or locally advanced cutaneous squamous cell carcinoma. Additionally, data readouts for several therapies are anticipated in the coming months, signaling progress in their clinical programs.
Read more →FBIOFortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-yea
Fortress Biotech reported record financial results for 2022, achieving consolidated net revenues of $75.7 million. The company plans to submit three new drug applications in 2023, including one for cosibelimab, which has received FDA filing acceptance. Management expressed confidence in their long-term growth prospects and the advancement of multiple clinical-stage programs. Despite these achievements, the company reported a significant non-GAAP net loss attributable to common stockholders.
Read more →FBIOFortress Biotech to Participate in Two March 2023 Investor Conferences
Fortress Biotech, Inc. (NASDAQ: FBIO) announced its participation in two upcoming investor conferences in March 2023. The CEO, Dr. Lindsay A. Rosenwald, will engage in a fireside chat at the 35th Annual ROTH Conference and present at the Oppenheimer 33rd Annual Virtual Healthcare Conference. Both events will include opportunities for one-on-one meetings with investors, with webcasts available afterward for wider accessibility. This participation reflects the company's ongoing commitment to communicating its growth strategy and product development to shareholders.
Read more →FBIOFortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Fortress Biotech, Inc. has successfully completed a registered direct offering and private placement, raising $13.9 million. The offering involved the issuance of 16.6 million shares at a price of $0.835 each. Directors and officers of Fortress participated in the offering, purchasing shares themselves. The proceeds will be used for general corporate purposes, reflecting the company's ongoing strategy for growth and expansion.
Read more →FBIOFortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Miami, FL
Fortress Biotech, Inc. has announced a registered direct offering to raise approximately $13.9 million by issuing 16.6 million shares at a price of $0.835 each. The offering, which is expected to close on February 10, 2023, involves participation from the company's directors and officers, with private placement investors receiving rights to acquire additional securities. However, the issuance of these rights is subject to stockholder approval, adding an element of risk to the transaction. The net proceeds are designated for general corporate purposes and working capital.
Read more →FBIOFortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors Miami, FL
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors Miami, FL - December 19, 2022 - Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising
Read more →FBIOFortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
MIAMI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates,
Read more →FBIOFortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million Cosibelimab BLA submission for met
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million Cosibelimab BLA submission for metastatic and locally advanced cutaneous squamous cell carci
Read more →FBIOFortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic
Read more →FBIOFortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candida
Read more →FBIOFortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squ
Read more →FBIOFortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announc
Read more →FBIOFORTRESS BIOTECH APPOINTS DAVID JIN AS CHIEF FINANCIAL OFFICER Miami, FL
FORTRESS BIOTECH APPOINTS DAVID JIN AS CHIEF FINANCIAL OFFICER Miami, FL - July 22, 2022 -- Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress" or the "Company"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing
Read more →FBIOFortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia Dotinurad was ef
Read more →FBIOFortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announce
Read more →FBIOFortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Net revenue for first quarter of 2022 increased 106% period-over-period to $23.9 million, a company quarterly record Positive
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Net revenue for first quarter of 2022 increased 106% period-over-period to $23.9 million, a company quarterly record Positive topline results from registration-enabling study of cosibe
Read more →FBIOFortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference
MIAMI, April 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announ
Read more →FBIOFortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announ
Read more →FBIOFortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights Record 2021: Net revenue of $68.8 million and proceeds from the successful monetization of our investment in Caelum Biosciences of $5
Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights 2021: Net revenue of $68.8 million and proceeds from the successful monetization of our investment in Caelum Biosciences of $56.9 million1 net loss attributable to common stockholders on a G
Read more →FBIOFortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting
Cyprium Therapeutics, a subsidiary of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease CUTX-101 has potential to be first FDA-approved treatment for Menkes disease; rolling submission of New Drug Application to FDA is ongoing and expected to be comple
Read more →FBIOFortress Biotech to Participate in Three March 2022 Investor Conferences
MIAMI, March 09, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announ
Read more →FBIOFortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
MIAMI, March 03, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announ
Read more →FBIOFortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference
MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, t
Read more →FBIOFortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference
MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, t
Read more →FBIOFortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively,
Read more →FBIOFortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
Helocyte, Inc., a partner company of Fortress Biotech, is developing Triplex for the treatment of cytomegalovirus Clinical trial will evaluate whether Triplex, which was developed by City of Hope, is safe and effective in eliciting a CMV-specific immune response in people living
Read more →FBIOFortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease
NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsid
Read more →FBIOFortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medica
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medical Corporation, a Fortress partner company, launched its
Read more →FBIOFortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively,
Read more →FBIOFortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition
Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease Overall survival significantly improved in patients treated with CUTX-101 Rolling submission of New Drug Application to the FDA for CUTX-101 planned to begin
Read more →FBIOFortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortr
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 New York, NY and Bordentown, NJ - October
Read more →FBIOFortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 AstraZeneca intends to advance and accelerate the Phase 3 development of CAEL-101 for light chain (AL) amyloidosis H
Read more →FBIOFortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech to Participate in Three September 2021 Investor Conferences
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record Rolling NDA s
Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record Rolling NDA submission for CUTX-101 for the treatment of Menkes dise
Read more →FBIOFortress Biotech to Participate in Three June 2021 Virtual Investor Conferences
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively,
Read more →FBIOFortress Biotech Announces Webinar Hosted by ROTH Capital Partners Featuring Partner Company Journey Medical Corporation
NEW YORK and SCOTTSDALE, Ariz., May 19, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candida
Read more →FBIOFortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On tra
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-ena
Read more →FBIOFortress Biotech, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before January 26, 2021; click here to submit trade information LOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Fortress Biotec
Read more →FBIOFortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe
Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure Dotinurad (URECE® tablet) was approved in Japan in 2
Read more →FBIOFortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOJourney Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA The first and only prescription cloth towelette approved to treat
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of ag
Read more →FBIOFortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019 Our partner company, Cyprium Therapeutic
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019 Our partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary
Read more →FBIOFortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane for the Treatment of Severe Recalcitrant Nodular Acne
NEW YORK and SCOTTSDALE, Ariz., March 22, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, in-licensed and launched an oral isotretinoin under the bran
Read more →FBIOFortress Biotech to Participate in Four March 2021 Virtual Investor Conferences
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectivel
Read more →FBIOFortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOCyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics' Copper Histidinate
Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics' Copper Histidinate Product Candidate for Treatment of Menkes Disease Sentyn
Read more →FBIOFortress Biotech to Participate in Three January 2021 Virtual Investor Conferences
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech Investors Who Have Suffered Losses Greater Than $50,000 Encouraged to Contact Kehoe Law Firm, P.C.
PHILADELPHIA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Fortress Biotech, Inc. (“Fortress Biotech” or the “Company”) (NASDAQ: FBIO) to determine whether the Company engaged in securities fraud or
Read more →FBIOFortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights Product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million Rolling submission of the New
Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights Product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million Rolling submission of the New Drug Application for CUTX-101 is expected to begin in the first quarter o
Read more →FBIOFortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners
NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis
- Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies - Phase 2 study met primary objective, supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients - Positive long-term Phas
Read more →FBIOFortress Biotech to Participate in Three September 2020 Virtual Investor Conferences
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectivel
Read more →FBIOFortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
Statistically Significant Improvement in the Primary Endpoint of Overall Survival in Menkes Disease Patients who Received Early Treatment with CUTX-101, Compared to an Untreated Historical Control, with a Nearly 80% Reduction in the Risk of Death (Hazard Ratio = 0.21, p<0.0001)
Read more →FBIOFortress Biotech Announces $60 Million Loan Agreement with Oaktree Capital Management
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech Announces Pricing of Series A Preferred Stock Offering New York, NY
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering New York, NY - August 26, 2020 - Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) ("Fortress"), an innovative biopharmaceutical company, today announced that it has pri
Read more →FBIOFortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively
Read more →FBIOFortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million Agreement executed with Columb
Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million Agreement executed with Columbia University to develop novel oligonucleotide platform
Read more →FBIOFortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical produc
Read more →FBIOFortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports
Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease A rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of 2020 NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: F
Read more →FBIOFortress Biotech Added to Russell 3000 Index
Avenue Therapeutics (ATXI), a Fortress partner company, also added NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed
Read more →FBIOFortress Biotech to Present at the Raymond James Human Health Innovation Conference
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical produc
Read more →FBIOFortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical produc
Read more →FBIOFortress Biotech to Host Virtual Annual Meeting of Stockholders
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”) virtually due to public health concerns
Read more →FBIOFortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights First quarter 2020 product revenue increased 95% year-over-year to $11.9 million NDA for IV tramadol accepted for revie
Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights quarter 2020 product revenue increased 95% year-over-year to $11.9 million IV tramadol accepted for review by FDA; assigned PDUFA date of October 10, 2020 executed with Columbia Univers
Read more →FBIOFortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers
Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides Initial target is KRAS-driven cancers, often considered “un-druggable” Platform being explored as a treatment for coron
Read more →FBIOFortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program New York, NY
Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program New York, NY - March 23, 2020 - Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress" or "the Company"), an innovative biopharmaceutical company focused on acqu
Read more →FBIOFortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights Revenue from marketed dermatology products increased 85% for fourth quarter 2019 and 49% for full-year 2
Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights Revenue from marketed dermatology products increased 85% for fourth quarter 2019 and 49% for full-year 2019 compared to 2018 NDA for IV tramadol accepted for re
Read more →FBIOFortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option
NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-stag
Read more →FBIOFortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease
NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced tha
Read more →FBIOFortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders
NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) today announced that Baergic Bio, Inc. (“Baergic”), a newly formed Fortress partner company, has entered into an exclusive worldwide licensing agreement with AstraZeneca for AZD7325, a
Read more →FBIOFortress Biotech to Participate in December 2019 Investor Conferences
NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced tha
Read more →FBIOFortress Biotech Ranked in Top 10 of Deloitte’s 2019 Technology Fast 500™
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced it
Read more →FBIOFortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights New York, NY - November 12, 2019 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing hig
Read more →FBIOFortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth Conference
NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced tha
Read more →FBIOFortress Biotech to Present at October 2019 Investor Conferences
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced th
Read more →FBIOFortress Biotech to Present at September 2019 Investor Conferences
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced th
Read more →FBIOFortress Biotech Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors New York, NY
Fortress Biotech Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors New York, NY - August 19, 2019 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potenti
Read more →FBIOFortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights New York, NY
Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights NY - August 9, 2019 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed an
Read more →FBIOFortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights New York, NY - May 10, 2019 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-pot
Read more →FBIOFortress Biotech Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Highlights New York, NY - March 18, 2019 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and de
Read more →FBIOFortress Biotech to Present at the 31st Annual ROTH Conference
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage assets, today announced that Lindsay A. Rosenwald, M.D., Chai
Read more →FBIOFortress Biotech Completes Final Stage Closing of the Sale of its Remaining Shares of National Holdings Corporation New York, NY
Fortress Biotech Completes Final Stage Closing of the Sale of its Remaining Shares of National Holdings Corporation New York, NY - February 12, 2019 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licens
Read more →FBIOFortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals
Fortress-founded Caelum Biosciences to receive $60 million in a strategic equity investment and option fee Alexion has option to acquire Caelum Biosciences based on Phase 2 data NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a bi
Read more →FBIOFortress Biotech Recaps Corporate Highlights and Achievements in 2018
NEW YORK, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today recapped its corporate highlights and achievem
Read more →FBIOFortress Biotech Announces Agreement to Sell Its Majority Stake in National Holdings Corporation to NHC Holdings, LLC, a wholly-owned subsidiary of B. Riley Financial New York, NY
Fortress Biotech Announces Agreement to Sell Its Majority Stake in National Holdings Corporation to NHC Holdings, LLC, a wholly-owned subsidiary of B. Riley Financial New York, NY - November 19, 2018 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical com
Read more →FBIOFortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY - November 9, 2018 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmac
Read more →FBIOFortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 (Copper Histidinate) for Menkes Disease in Molecular Therapy: Methods & Clinical Development
NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced the publication of preclinical data
Read more →FBIOFortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY - August 9, 2018 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmace
Read more →FBIOFortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Pennsylvania to Advance AAV Gene Therapy Technology
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that its subsidiary, Aevitas Therapeutics,
Read more →FBIOFortress Biotech Announces Cyprium Therapeutics’ CUTX-101 (Copper Histidinate) Granted FDA Fast Track Designation for Treatment of Classic Menkes Disease
NEW YORK, July 02, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that the U.S. Food and Drug Administr
Read more →FBIOFortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that data from a Phase 1 clinical trial eva
Read more →FBIOFortress Biotech Appoints Michael G. King, Jr. as Entrepreneur in Residence
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Michael G. King, Jr. has been app
Read more →FBIOFortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY - May 10, 2018 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceuti
Read more →FBIOFortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights New York, NY
Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights New York, NY - March 16, 2018 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel phar
Read more →FBIOFortress Biotech to Present at Oppenheimer’s 28th Annual Healthcare Conference
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., Cha
Read more →FBIOFortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School to Advance AAV Gene Therapies
SRA with lab of Guangping Gao, Ph.D., to explore construct optimization in AAV gene therapies for complement-mediated diseases Dr. Gao to serve as first member of Aevitas’ recently launched scientific advisory board NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (
Read more →FBIOFortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (“Fortress”) (NASDAQ:FBIO), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that its senior management team will
Read more →FBIONon - Confidential Materials Corporate Presentation December 2017 Non - Confidential Materials Forward Looking Statements This presentation may contain "forward - looking statements" within the meaning of Section 27A of
Non - Confidential Materials Corporate Presentation December 2017 Non - Confidential Materials Forward Looking Statements This presentation may contain "forward - looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securitie
Read more →FBIOFortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting
Columbia University reports Caelum Biosciences’ CAEL-101 was well tolerated, demonstrated early and clinically efficacious organ response in Phase 1a/1b trial in AL amyloidosis City of Hope announces Mustang Bio’s MB-102 (CD123 CAR) achieves first-reported complete response from
Read more →FBIOFortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet Medical Needs
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced the formation of Tamid Bio, Inc. (“T
Read more →FBIOFortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights New York, NY
Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights New York, NY - November 9, 2017 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical an
Read more →FBIOFortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury
Designation to facilitate expedited development and review of CEVA101 for TBI CEVA101 is being developed in partnership with The University of Texas Health Science Center at Houston (UTHealth) NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fo
Read more →FBIOFortress Biotech Announces Pricing of Series A Preferred Stock Offering
NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that it has priced an underwritten pu
Read more →FBIOFortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that data from two of its subsidiarie
Read more →FBIOFortress Biotech Announces Proposed Public Offering of Series A Preferred Stock
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that it intends to offer and sell sha
Read more →FBIOFortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., For
Read more →FBIOFortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq:FBIO) today announced the formation of a new subsidiary company, Aevitas Therapeutics, Inc. (“Aevitas”), to develop novel gene therapy approaches for complement-mediated diseases. The proprietary technolog
Read more →FBIOFortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights New York, NY - August 9, 2017 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmace
Read more →FBIOFortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101
NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Columbia University (“Columbia”)
Read more →FBIOFortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics
NEW YORK, July 03, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, announced that Lucy Lu, MD, has been named President
Read more →FBIOFortress Biotech to Present at the 2017 BIO International Convention
NEW YORK, June 15, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., Fort
Read more →FBIOFortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies
NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Mustang Bio, Inc. (“Mustang”), a
Read more →FBIOFortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon
NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that its subsidiary Caelum Bioscience
Read more →FBIOFortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights New York, NY - May 10, 2017 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceuti
Read more →FBIOFortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis
CAEL-101 is in development by Fortress subsidiary Caelum Biosciences Preliminary Phase 1b data expected mid-2017; full data readout anticipated in late 2017 Phase 2 study planned for the first half of 2018 NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASD
Read more →FBIOProprietary Materials Corporate Presentation May 2017 Proprietary Materials Forward Looking Statements This presentation may contain "forward - looking statements" within the meaning of Section 27A of the Securities Act
Proprietary Materials Corporate Presentation May 2017 Proprietary Materials Forward Looking Statements This presentation may contain "forward - looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1
Read more →FBIOFortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., For
Read more →FBIOFortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis
NEW YORK, April 05, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that the U.S. Department of Health &
Read more →FBIOFortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference
NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., For
Read more →FBIOFortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended
Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016 New York, NY - March 16, 2017 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel
Read more →FBIOFortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders
Cyprium, NICHD establish CRADA to advance clinical development of Phase 3 candidate CUTX-101 (Copper Histidinate injection) in Menkes disease, a rare and fatal pediatric disease Cyprium licenses preclinical AAV-ATP7A gene therapy from NICHD to develop in combination with CUTX-10
Read more →FBIOFortress Biotech to Present at the 29th Annual ROTH Conference
NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., For
Read more →FBIOProprietary Materials Corporate Presentation Lindsay A. Rosenwald , MD President and CEO Chairman of the Board March 2017 Proprietary Materials Forward Looking Statements This presentation may contain "forward - looking
Proprietary Materials Corporate Presentation Lindsay A. Rosenwald , MD President and CEO Chairman of the Board March 2017 Proprietary Materials Forward Looking Statements This presentation may contain "forward - looking statements" within the meaning of Section 27A of the Securi
Read more →FBIOCorporate Overview March , 2017 CAELUM BIOSCIENCES Forward Looking Statements 2 Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the "sa
Corporate Overview March , 2017 CAELUM BIOSCIENCES Forward Looking Statements 2 Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
Read more →FBIOProprietary Materials Corporate Presentation Lindsay A.
Proprietary Materials Corporate Presentation Lindsay A. Rosenwald , MD President and CEO Chairman of the Board February 2017 Proprietary Materials Fortress Biotech 2 This presentation may contain "forward - looking statements" within the meaning of Section 27A of the Securities
Read more →FBIOFortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing Proceeds will support clinical development and expansion of Mustang Bio's CAR T immunotherapy pipeline New Yor
Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing Proceeds will support clinical development and expansion of Mustang Bio's CAR T immunotherapy pipeline New York, NY - February 2, 2017 - Fortress Biotech, Inc. (NASD
Read more →FBIOFortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis
Caelum Program Evaluating CAEL-101 (11-1F4) for AL Amyloidosis In-licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 is safe and well tolerated; 67 percent of patients showed impro
Read more →FBIOUNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS The accompanying unaudited pro forma condensed combined financial statement of Fortress Biotech, Inc. ("Fortress", "FBIO" or the "Company") is presented to illustrate the
UNAUDITED PRO FORMA COMBINED FINANCIAL The accompanying unaudited pro forma condensed combined financial statement of Fortress Biotech, Inc. ("Fortress", "FBIO" or the "Company") is presented to illustrate the estimated effects of the acquisition of a majority equity stake in,
Read more →FBIOFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY - November 9, 2016 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmac
Read more →FBIOFortress Biotech Forms New Subsidiary, Cellvation, Inc., to Develop Novel Therapies for the Treatment of Traumatic Brain Injury
Cellvation to Advance Three Programs Licensed from UTHealth Two Phase 2 Studies Supported by Approximately $10M in Secured Grant Funding Frank Taffy to Serve as Interim Chief Executive Officer NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc., (NASDAQ:FBIO) ha
Read more →FBIOCORPORATE OVERVIEW NASDAQ : FBIO October 2016
CORPORATE OVERVIEW NASDAQ : FBIO October 2016 FORWARD - LOOKING STATEMENTS Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the " safe harbor " provisions of the Private Securities Litigation Ref
Read more →FBIOFortress Biotech Completes Tender Offer for Shares of National Holdings Corporation
NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress” or “FBIO”) and National Holdings Corporation (NASDAQ:NHLD) (“NHLD”) today announced that an affiliate of Fortress, FBIO Acquisition, Inc., has completed its previously announced tender o
Read more →FBIOFortress Biotech Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights -Quarter Milestones Include Commercialization of First Two Products- New York, NY
Fortress Biotech Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights -Quarter Milestones Include Commercialization of First Two Products- New York, NY - August 9, 2016 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company
Read more →FBIOCheckpoint Therapeutics, Inc. 2 Gansevoort Street, 9 th Floor New York, NY 10014 Tel: +1-781-652-4500 www.checkpointtx.com Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida - 201301, India Tel.: +91 120 4361000 www.jubl.
Jubilant Biosys Enters into Exclusive out - Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors New York, NY, USA, Fridayy, Noida (UP), India, Friday, May Jubilant Biosys Ltd ("Jubilant Biosys"), a subsidiary of Jubilant Life Sciences Ltd, and Checkpoin
Read more →FBIOFortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia at the Innate Killer Summit 2016
NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, announced positive data from the Phase 1/2 study of CNDO-109-Activated Al
Read more →FBIOFortress Biotech Reports First Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY
Fortress Biotech Reports First Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY - May 10, 2016 - Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceuti
Read more →FBIOMustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13R 2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19 th Annual Meeting Early clinica
Mustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13R 2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19th Annual Meeting Early clinical findings suggest IL13R 2-targeted CAR T cells is safe a
Read more →FBIOFortress Biotech and National Holdings Announce Agreement Subsidiary of Fortress Biotech to make $3.25/share tender offer for all outstanding National Holdings shares If less than 80% of outstanding shares are tendered,
Biotech and National Holdings Announce Agreement Subsidiary of Fortress Biotech to make $3.25/share tender offer for all outstanding National Holdings shares of outstanding shares are tendered, National Holdings will remain publicly-traded Shareholders post-tender offer to re
Read more →FBIOHELOCYTE ANNOUNCES CORPORATE AND CLINICAL MILESTONES Frank Taffy Appointed President and Chief Executive Officer Lead Immunotherapies PepVax and Triplex Advanced into Phase 2 Triplex Phase 1 Data Presented at ASH PepVax
HELOCYTE ANNOUNCES CORPORATE AND CLINICAL New York, New York - April 21, 2016 - Helocyte, Inc. a majority-owned subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) focused on the acquisition, development and commercialization of novel immunotherapies for the prevention and tre
Read more →FBIOMustang Bio Announces Presentations of MB-101, a Novel IL13R 2-specific CAR-T cells Product in Clinical Development, at the American Society of Gene and Cell Therapy 19 th Annual Meeting New York, NY
Mustang Bio Announces Presentations of MB-101, a Novel IL13R 2-specific CAR-T cells Product in Clinical Development, at the American Society of Gene and Cell Therapy New York, NY - April 18, 2016 - Mustang Bio, Inc. ("Mustang"), a Fortress Biotech (NASDAQ: FBIO) Company, today
Read more →FBIOFortress Biotech Reports Financial Results for the Fourth Quarter and Year Ended
Fortress Biotech Reports Financial Results for the Fourth Quarter and Year Ended New York, NY - March 15, 2016 - Fortress Biotech, Inc. (NASDAQ: FBIO) announces its financial results for the fourth quarter and year ended December 31, Dr. Lindsay A. Rosenwald, Fortress Biotech
Read more →FBIOTeva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor Checkpoint to Obtain Exclusive Worldwide Development and Commercialization Rights Jerusalem and New York, NY, January 7 , 2016 - Teva Ph
Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor Checkpoint to Obtain Exclusive Worldwide Development and Commercialization Rights New York, NY, January 7, 2016 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Checkpoint Ther
Read more →FBIOAvenue Therapeutics Files to Become a Public Reporting Company New York, NY
Avenue Therapeutics Files to Become a Public Reporting Company New York, NY - December 30, 2015 - Avenue Therapeutics, Inc. ("Avenue"), a Fortress Biotech, Inc. (NASDAQ: FBIO) Company, announced that it filed a registration statement on Form 10 with the Securities and Exchang
Read more →FBIOCheckpoint Therapeutics Closes $58M in Private Placement Financing New York, NY
Checkpoint Therapeutics Closes $58M in Private Placement Financing New York, NY - December 21, 2015 - Checkpoint Therapeutics, Inc. ("Checkpoint"), a Fortress Biotech (NASDAQ: FBIO) Company, announced today that it has closed on a total of $58 million, before commissions and
Read more →FBIOFORTRESS BIOTECH REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER 2015 ENDED SEPTEMBER 30, 2015 New York, NY
FORTRESS BIOTECH REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER 2015 ENDED New York, NY - November 9, 2015 - Fortress Biotech, Inc. (NASDAQ: FBIO) announces its financial results for the third quarter ended September 30, 2015. Dr. Lindsay A. Rosenwald, Fortress Biotech's Cha
Read more →FBIOAvenue Therapeutics, Inc. Corporate Overview October 2015 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of th
Avenue Therapeutics, Inc. Corporate Overview October 2015 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the " safe harbor " provisions of the Private Securities Liti
Read more →FBIOCheckpoint Therapeutics Files to Become a Public Reporting Company New York, NY
Checkpoint Therapeutics Files to Become a Public Reporting Company New York, NY - September 8, 2015 - Checkpoint Therapeutics, Inc. ("Checkpoint"), a Fortress Biotech Company, (NASDAQ: FBIO) announced that it filed a registration statement on Form 10 with the Securities and E
Read more →FBIOFORTRESS BIOTECH REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER 2015 ENDED JUNE 30, 2015 New York, NY
FORTRESS BIOTECH REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER 2015 ENDED New York, NY - August 10, 2015 - Fortress Biotech, Inc. (NASDAQ: FBIO) announces its financial results for the second quarter ended June 30, 2015. "This was another exciting quarter as we continued t
Read more →FBIOFortress Biotech Subsidiary, Altamira Bio, Acquires NIH License and CRADAs Relating to the Development of N-acetyl-D-mannosamine (ManNAc) for Rare Genetic Disorders
NEW YORK, July 17, 2015 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) announced that its subsidiary, Altamira Bio, acquired from New Zealand Pharmaceuticals Ltd (NZP), a license from the National Institutes of Health (NIH) and Cooperative Research and Development Agree
Read more →FBIOFORTRESS BIOTECH REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER 2015 ENDED MARCH 31, 2015 New York, NY
FORTRESS BIOTECH REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER 2015 ENDED New York, NY - May 11, 2015 - Fortress Biotech, Inc. (NASDAQ: FBIO) announces its financial results for the first quarter of 2015 ended March 31, 2015. "This was a very busy and productive quarter as
Read more →FBIOCORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2014 Burlington, MA
CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2014 Burlington, MA - March 16, 2015 - Coronado Biosciences, Inc. (NASDAQ: CNDO) announced its financial results for the fourth quarter and year ended December 31, 2014. Dr. Lind
Read more →FBIOCORONADO BIOSCIENCES CLOSES $10 MILLION PRIVATE PLACEMENT FINANCING Burlington, MA
CORONADO BIOSCIENCES CLOSES $10 MILLION PRIVATE PLACEMENT FINANCING Burlington, MA - March 3, 2015 - Coronado Biosciences, Inc. (NASDAQ: CNDO) announces that it has closed a private placement of a promissory note for $10 million. The Company intends to use the proceeds from t
Read more →FBIOCORONADO BIOSCIENCES RAISES $3,500,000
CORONADO BIOSCIENCES RAISES $3,500,000 THROUGH THE PRIVATE PLACEMENT OF RESTRICTED COMMON STOCK Shares were sold at the closing price on November 6, 2014 Participating in the transaction were DAK Capital and Officers and Directors, Dr. Lindsay A. Rosenwald, Michael S. Weiss a
Read more →FBIOAltamira Bio, Inc.
Altamira Bio, Inc. Formerly TSO Development Corp. A wholly owned subsidiary of Coronado Biosciences November 2014 Forward - Looking Statements Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the
Read more →FBIOCORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS Burlington, MA
CORONADO BIOSCIENCES REPORTS FINANCIAL Burlington, MA - November 6, 2014 - Coronado Biosciences, Inc. (NASDAQ: CNDO) announced its financial results for the third quarter ended September 30, 2014. Coronado's net cash and restricted cash totaled $71.6 million and $15.4 million
Read more →FBIOCoronado Biosciences Reports Topline Results from Investigator Initiated Pilot Study of TSO in Adults with Autism Spectrum Disorder Burlington, MA
Coronado Biosciences Reports Topline Results from Investigator Initiated Pilot Study of TSO in Adults with Autism Spectrum Disorder Burlington, MA - June 26, 2014 - Coronado Biosciences, Inc. (NASDAQ; CNDO) today announced that Dr. Eric Hollander, Clinical Professor Psychiatry
Read more →FBIOCORONADO BIOSCIENCES INITIATES PHASE 2A CLINICAL STUDY OF TSO IN PEDIATRIC PATIENTS WITH AUTISM SPECTRUM DISORDER Burlington, MA
CORONADO BIOSCIENCES INITIATES PHASE 2A CLINICAL STUDY OF TSO IN PEDIATRIC PATIENTS WITH AUTISM SPECTRUM DISORDER Burlington, MA - May 14, 2014 - Coronado Biosciences, Inc. (NASDAQ: CNDO) today announced that it has initiated a Phase 2a clinical trial of TSO (Trichuris suis ov
Read more →FBIOCORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2014 Burlington, MA
CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED Burlington, MA - May 12, 2014 - Coronado Biosciences, Inc. (NASDAQ: CNDO) announced today its financial results for the first quarter ended March 31, 2014. "We are making progress on multiple fronts,"
Read more →FBIONASDAQ: CNDO April 2014 Lindsay A. Rosenwald, MD Chairman, President and CEO Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the " safe
NASDAQ: CNDO April 2014 Lindsay A. Rosenwald, MD Chairman, President and CEO Statements in this presentation that are not descriptions of historical facts are forward - looking statements within the meaning of the " safe harbor " provisions of the Private Securities Litigation R
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES INITIATION OF INVESTIGATOR-INITIATED STUDY EVALUATING TSO IN PEDIATRIC PATIENTS WITH AUTISM SPECTRUM DISORDER Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES INITIATION OF INVESTIGATOR-INITIATED STUDY EVALUATING TSO IN PEDIATRIC PATIENTS WITH AUTISM SPECTRUM DISORDER Burlington, MA - April 10, 2014 - Coronado Biosciences, Inc. (NASDAQ: CNDO) today announced that an Investigator-Initiated Study evaluat
Read more →FBIOCORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2013 Burlington, MA
CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2013 Burlington, MA - March 14, 2014 - Coronado Biosciences, Inc. (NASDAQ: CNDO) today announced its financial results for the fourth quarter and year ended December 31, 2013. "G
Read more →FBIOCORONADO BIOSCIENCES GRANTED A SECOND KEY PATENT FOR CNDO-109, AN ACTIVATOR OF NATURAL KILLER CELLS Burlington, MA
CORONADO BIOSCIENCES GRANTED A SECOND KEY PATENT FOR CNDO-109, AN ACTIVATOR OF NATURAL KILLER CELLS Burlington, MA - February 6, 2014 - Coronado Biosciences, Inc. (NASDAQ:CNDO), a biopharmaceutical company involved in the development of novel immunotherapy agents for the treat
Read more →FBIOStatements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We ha
Compositions and Methods for Treating Viral Infections * Expiration dates do not include any patent term extension CNDO 109 Intellectual Property CNDO 109 Intellectual Property 17 Financials Financials 18 Listed on NASDAQ: CNDO Market Cap as of 12/20/2013 ~$75M Shares Outstanding
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES MANAGEMENT CHANGES Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES MANAGEMENT CHANGES Burlington, MA- December 20, 2013- Coronado Biosciences, Inc. (NASDAQ:CNDO), a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, as well as t
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES PRESENTATION OF INTERIM DATA FROM AUTISM STUDY AT NEUROPSYCHOPHARMACOLOGY MEETING STUDY INVESTIGATOR ERIC HOLLANDER, M.D., REPORTS POTENTIAL BENEFITS OF TSO IMMUNOTHERAPY IN FIRST 5 PATIENT
CORONADO BIOSCIENCES ANNOUNCES PRESENTATION OF INTERIM DATA FROM AUTISM STUDY AT NEUROPSYCHOPHARMACOLOGY Burlington, MA December 12, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company developing novel immunotherapy agents for the treatment of autoimmune
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES IND SUBMISSION FOR TSO FOR THE TREATMENT OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES IND SUBMISSION FOR TSO FOR THE TREATMENT OF MODERATE TO SEVERE CHRONIC Burlington, MA December 9, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatmen
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION TO DISCONTINUE FALK PHASE 2 Trial of TSO in CROHN S DISEASE Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION TO DISCONTINUE FALK PHASE 2 Trial of TSO in CROHN S DISEASE Burlington, MA November 6, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES PERSONNEL REALIGNMENT, INCLUDING APPOINTMENT OF KEVIN HORGAN, M.D., AS CHIEF MEDICAL OFFICER Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES PERSONNEL REALIGNMENT, INCLUDING APPOINTMENT OF KEVIN HORGAN, M.D., AS CHIEF MEDICAL OFFICER Burlington, MA November 6, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy
Read more →FBIOCoronado Biosciences Reports Financial Results for the Third Quarter Ended
Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2013 Burlington, MA November 1, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatme
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES TOP-LINE RESULTS FROM ITS TRUST-I PHASE 2 CLINICAL TRIAL OF TSO FOR THE TREATMENT OF CROHN S DISEASE -Company to Host Conference Call Today
CORONADO BIOSCIENCES ANNOUNCES TOP-LINE RESULTS FROM ITS TRUST-I PHASE 2 CLINICAL TRIAL OF TSO FOR THE TREATMENT OF CROHN S DISEASE -Company to Host Conference Call Today, October 14, 2013 at 9:00AM ET to Discuss Results Burlington, MA October 14, 2013 Coronado Biosciences, In
Read more →FBIOCORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2013 Burlington, MA
CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2013 Burlington, MA August 5, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT IN TRUST-I PHASE 2 CLINICAL TRIAL OF TSO FOR CROHN S DISEASE Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT IN TRUST-I PHASE 2 CLINICAL TRIAL OF TSO FOR Burlington, MA July 1, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the trea
Read more →FBIOCORONADO BIOSCIENCES APPOINTS GEORGE AVGERINOS, PH.D. AS SENIOR VICE PRESIDENT, BIOLOGICS OPERATIONS Burlington, MA
CORONADO BIOSCIENCES APPOINTS GEORGE AVGERINOS, PH.D. AS SENIOR VICE PRESIDENT, BIOLOGICS OPERATIONS Burlington, MA June 4, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the trea
Read more →FBIOCORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2013 Burlington, MA
CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2013 Burlington, MA May 8, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of aut
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES DEPARTURE OF DR. BOBBY W. SANDAGE, JR. Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES DEPARTURE OF DR. BOBBY W. SANDAGE, JR. Burlington, MA April 24, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases
Read more →FBIOCORONADO BIOSCIENCES ANNOUNCES SALE OF COMMON STOCK IN ITS AT-THE-MARKET PUBLIC OFFERING Burlington, MA
CORONADO BIOSCIENCES ANNOUNCES SALE OF COMMON STOCK IN ITS AT-THE-MARKET PUBLIC OFFERING Burlington, MA April 11, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of a
Read more →FBIOCORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2012 Burlington, MA
CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED Burlington, MA March 14, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoi
Read more →FBIOCoronado Biosciences signs Research Collaboration and License Agreement With Freie Universit t Berlin for Secretory Products of Trichuris suis Burlington, MA
Coronado Biosciences signs Research Collaboration and License Agreement With Freie Universit t Berlin for Secretory Products of Trichuris suis Burlington, MA February 22, 2013 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of
Read more →FBIOCoronado Biosciences Announces Key Addition to Management Team Burlington, MA
Coronado Biosciences Announces Key Addition to Management Team Burlington, MA, January 2, 2013 (GLOBE NEWSWIRE) Coronado Biosciences, Inc. (NASDAQ:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmun
Read more →FBIOCORONADO BIOSCIENCES ACQUIRES TSO MANUFACTURING RIGHTS FROM OVAMED Burlington, MA
CORONADO BIOSCIENCES ACQUIRES TSO MANUFACTURING RIGHTS FROM OVAMED Burlington, MA December 27, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases
Read more →FBIOSeptember 2012 Bobby W. Sandage, Jr., PhD President Chief Executive Officer Developing Unique Products for Autoimmune Diseases and Cancer (NASDAQ: CNDO) Statements in this presentation that are not descriptions of histor
Cooper, MD Executive Chairman Served as Chairman CEO of Indevus Pharmaceuticals, Inc. Over 25 years of pharmaceutical/biotechnology experience Eric K. Rowinsky, MD Vice Chairman World renown oncologist, former CMO at ImClone, board of Over 25 years of healthcare experience Lindsa
Read more →FBIOCORONADO BIOSCIENCES SECURES $15 MILLION LOAN FACILITY FROM HERCULES TECHNOLOGY GROWTH CAPITAL Burlington, MA
CORONADO BIOSCIENCES SECURES $15 MILLION LOAN FACILITY FROM HERCULES TECHNOLOGY GROWTH CAPITAL Burlington, MA August 29, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatme
Read more →FBIOCoronado Biosciences Reports Financial Results for the Second Quarter Ended
Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2012 Burlington, MA August 8, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmun
Read more →FBIOCORONADO BIOSCIENCES, INC. ANNOUNCES THE PRICING OF PUBLIC OFFERING OF COMMON STOCK Burlington, MA
CORONADO BIOSCIENCES, INC. ANNOUNCES THE PRICING OF PUBLIC OFFERING OF COMMON STOCK Burlington, MA June 22, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimm
Read more →FBIOCoronado Biosciences Reports Financial Results for the First Quarter Ended
Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2012 Burlington, MA May 15, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune
Read more →FBIOCoronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn s Disease No Safety Issues Noted Burlington, MA
Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn s Disease No Safety Issues Noted Burlington, MA April 24, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on t
Read more →FBIOCoronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended
Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011 Burlington, MA March 29, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment
Read more →FBIOCoronado Biosciences Signs Collaboration Agreement with Dr. Falk Pharma and OvaMed for the Development of TSO for Crohn s Disease Burlington, MA
Coronado Biosciences Signs Collaboration Agreement with Dr. Falk Pharma and OvaMed for the Development of TSO for Crohn s Disease Burlington, MA March 22, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherap
Read more →FBIOCoronado Biosciences Signs Binding Terms of Agreement to enter into Collaboration for Development of CNDO-201 for Crohn s disease with Dr. Falk Pharma and OvaMed Burlington, MA
Coronado Biosciences Signs Binding Terms of Agreement to enter into Collaboration for Development of CNDO-201 for Crohn s disease with Dr. Falk Pharma and OvaMed Burlington, MA December 22, 2011 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on th
Read more →FBIOCoronado Biosciences Approved for Listing on NASDAQ Burlington, MA
Coronado Biosciences Approved for Listing on NASDAQ December 15, 2011 Coronado Biosciences, Inc., (OTCBB: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that its com
Read more →FBIOCoronado Biosciences Commences Public Trading on the OTC Bulletin Board Form S-1 Registration Statement Declared Effective by SEC Burlington, MA
Coronado Biosciences Commences Public Trading on the OTC Bulletin Board Form S-1 Registration Statement Declared Effective by SEC Burlington, MA November 17, 2011 Coronado Biosciences, Inc. (OTCBB: CNDO.OB), a company focused on novel immunotherapy biologic agents for the treat
Read more →Competitive Position
How FBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how FBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial